Accrol Group Holdings plc is a leading independent tissue converter, manufacturing toilet rolls, kitchen rolls, facial tissues and AFH products to supply retailers throughout the UK. Accrol imports parent reels from around the world and converts them into finished goods at the Company’s 350,000 sq. ft. manufacturing, storage and distribution facility in Blackburn, Lancashire. Accrol currently manufactures approximately 17 million units per week and supplies some of the UK’s largest retailers.

Accrol Group Holdings plc is listed on AIM, the growth market of the London Stock Exchange.

The Company was incorporated and registered in England and Wales on 30 April 2014 under the Act with registered number 9019496 as a private company limited by shares with the name Aghoco 1220 Limited. The name of the Company was changed to Accrol Group Holdings Limited on 1 August 2014. The Company was re-registered as a public limited company with the name Accrol Group Holdings plc on 1st June 2016. Accrol Group Holdings plc’s main country of operation is the UK.

The Company, and the Group, trade under the name “Accrol Papers”.

Shares - Loo roll manufacturer Accrol (ACRL:AIM) has a satisfying start to life as a listed company, with the shares soaring 10% to 110p.

The company, which converts industrial paper reels into toilet paper, facial tissues and hand towels, has joined the AIM market with a market capitalisation of £93 million pre-share price surge.

It has raised £63.5 million which it will use to repay shareholder loan notes and refinance debt.

Accrol also hopes that the IPO, first announced in May, will increase its profile and help its expansion plans.

Chief financial officer James Flude previously told Shares there is a big opportunity to grow its market share in the supermarket sector, which currently stands at just 7%.

Accrol also has a 35% market share of the discount sector, which is growing rapidly.

The group claims it can pay an eye-catching dividend yield of 6% thanks to its cash generative model of buying and converting reels as oppose to manufacturing them.

1440000 rolls produced today

2500 pallets stacked today

82 lorries loaded today

63 customer deliveries today

Hi Dreamcatcher

I don't usually post except for the FTSE competition, however these are a really good company.

I use them professionally in the AFH market (Away from Home) so Hotels, Education, Care Sector, everyone needs tissue products as does every industry you can think of for wiping (not just toilet rolls) engineering wipers, forecourt rolls for petrol stations the list is endless, not just discount retailers.

Was really pleased they floated and I dived straight in, didn't get the best price, but don't care, this will just go up and up and up, in my opinion DYOR

Thanks stevesham. Feel free to post. :-)) I'm in as well. The supply to the supermarkets interested me, especially supplying the German discounters. Should be a very fast growing market. Also the dividend yield of 6%.

From Shares - Chief financial officer James Flude previously told Shares there is a big opportunity to grow its market share in the supermarket sector, which currently stands at just 7%.

Accrol also has a 35% market share of the discount sector, which is growing rapidly.

Thanks Dreamcatcher

I agree with James Flude and would add I feel big brands are losing market share as converters which Accrol are continue to produce better and better products without the need for expensive marketing and TV campaigns, just quality products at prices for everyone.

Again don't lose sight of the AFH market which generally view tissue products as a cost so want to purchase quality at cheaper prices which is where Accrol sit very nicely, and there are also significant volumes there, along with Janitorial Distributors selling Accrol products to their customers, and generally minimum order from Accrol run to at least 10 pallets at a time to get a half decent price to re-sell, but even better if the distributor can run to 20 or more.

Take an average school, maybe there are 500 kids, that's a lot of toilet tissue, hand towels, wiping rolls, multiply that by the number of schools, academies, universities across the UK and further afield that equates to hundreds of thousands of people using their products, couple that with an increasing population and the Accrol factory set-up for volume, why wouldn't this just keep on growing?

Just waiting for some price movement and will keep topping up as and when I can, for me at least a great buy and hold

Cheers stevesham.


paragraph from the the intention to float on the aim market document dated 26 May 16.

Macro-economic impact on raw material prices - There is currently a global over-supply of both pulp and Parent Reels, with additional capacity forecast to be brought on stream through to 2019. As such, Parent Reel prices are currently relatively low and are expected to remain so for the foreseeable future. Low Parent Reel prices allow Accrol to manufacture at a lower cost, enhancing margin and providing pricing flexibility to win new orders. Overcapacity drives increased flexibility of supply and provides Accrol with a choice of pricing and technology when sourcing Parent Reels.

My take on that, having been through so many pulp price cycles, in real terms what I believe will happen as it has done numerous times and the same goes for polythene extruders with oil price volatility is...

If pulp goes up the whole market will move up their price points, it is quite interesting to watch, one of the big names usually starts first Kimberly Clark, SCA for example then some of the larger converters Accrol being one of them along with others and then the smaller ones as they generally try to pick up market share having fewer overheads.

That said, I think we have reached the stage that no-one wants to use cut up newspaper so even if the prices move up, there is still a growing market, so even if margins are squeezed increasing volumes as long as the business model remains should still be fine.

Now the biggest challenge as with any business and with new people at the top is to keep costs under control as they always have run very lean and keen.

Just my thoughts

Keep your thoughts rolling. You sound very knowledgeable. :-))

Thanks Dreamcatcher I work in the industry

:-))

We may be coming out of Europe, but we will still need toilet rolls!

Even more today. :-)) Just hope raw material cost does not rise to sharply. As you said before, it will have to be passed on.

I payed just under 111p per share.

Indeed :-))

Fared well today considering.

I got in at just over £1.11, but as I said before I am happy with this, I am not a frantic day trader this is one to tuck away and watch it grow, just waiting for the dust to settle from the referendum and then I intend to top up.

As you, I thought it held up well with everything else just falling through the floor (with the odd exception. maybe because to many a toilet roll company is just too dull, boring and uninspiring which suits me perfectly ;-) therefore not a lot of activity.

Also at the end of the day, it doesn't need to pay for European/Eastern European temporary workers like fruit and veg farmers, expensive agency staff like the NHS, just solid jobs for hard working people a true 'bucket and spade' business which again is another big tick in the box for me.

Stevesham, looking back I see they were going to purchase their own paper mill. Just wonder if it will still be something for the future?

Good question, I didn't know that I may ask them as for me at least the simplest business model would be to continue converting parent reels for the following reasons

1. Wider choice of suppliers from the major mills already operating for example Kimberly Clark, SCA, Metsa Tissue, Georgia Pacific being the main ones however https://en.wikipedia.org/wiki/List_of_paper_mills there are dozens

2. Additional Environmental legislation to conform with as water, chemicals have to be disposed of as there will no doubt be an element of recycled paper going through the mill, and if it is newsprint for example it has to be chemically whitened as dull grey tissue is not that appealing

3. Cost of equipment and energy to heat and run versus the low potential savings, but to balance that, if Accrol did maunfacture the paper they could also sell the parent reels into the market

4. I like simple, let others have the hassle of owning and managing the forests, planting the trees, pulping the wood etc, unless of course it was purely recycled paper which is not in my view as good virgin fibre because when paper is recycled it is put back together with glue and the length of the fibres are shorter than virgin fibre right off the tree

I could go on, but I am starting to get boring, but one final piece of information is the amount of different properties of paper and tissue demanded by the market for different applications.

Softness for skin contact

Wet strength for example when used catering environments doesn't break down when wiping kitchen surfaces

General Absorbency

Low linting for use at electronic producers and other industries where dust is their enemy

Absorbency for oils and grease

Polishing cloths for the automotive and other industries

All different properties are manufactured in different ways, and we won't go on about roll size, dispenser options, 1ply, 2ply, 3ply

Suffice it to say the market for tissue and paper products is vast, just talking about the UK, every home, building, workplace, hotel, school, university, care home, restaurant, factory and person uses paper and tissue daily and with around 64 million people around, that is one of the largest target markets ever, and the final point (again) is the product is used generally once and then thrown away and bought again giving phenomenal repeat business.

Just my pennies worth, think I am going to buy a paper convertor :-)))) oopps already have shares in Accrol, note to self buy more

DYOR......

Thanks for your knowledge and efforts. Going to sit on my hands at the moment incase severe shock waves hits the markets. Rather surprised on Friday that the outcome was not far worse. Looks like banks and builders took the brunt.

Well, what can I say, more of the same please, good luck everyone

Accrol Group Holdings plc (the "Company" or "Accrol")

Contract Win and Trading Update


Accrol Group Holdings plc, the AIM listed leading independent tissue converter, is pleased to announce that it has agreed a new contract with a major global retailer to supply toilet paper, kitchen rolls and facial tissues with revenues expected to be more than £10 million per annum at manufacturer's selling price.

The new contract further consolidates Accrol's position as a leading player within the marketplace and will commence in Autumn 2016 using existing manufacturing capacity.

In the event that there is a period of reduced consumer expenditure following the UK's decision to leave the European Union, it is possible that the move towards non-discretionary economy and private label products will accelerate. If this happens, Accrol believes it is well positioned to benefit as over 50% of sales are generated from the discount market segment and the Company is primarily focused on supplying private label products to both discount and multiple retailers.

The Company remains significantly hedged against adverse currency movements for the financial year ending 30 April 2017. Moreover, whilst only two months of this financial year have passed, the directors are comfortable with market forecasts and continue to see opportunities in the market. Results for the year ended 30 April 2016 will be announced on 22 July 2016.

Steve Crossley, Accrol's newly appointed CEO commented: "We are delighted that another major global retailer has chosen Accrol as a supplier for its tissue products. This is a great start to Accrol's life as a publicly listed company and represents a major business win that will contribute significantly to our future growth".

Good news. Not flagged by moneyam ?

AOL. - Benefitting from Brexit?

Also reporting today was Accrol Group(LSE: ACRL), with the independent tissue converter announcing a new contract with a major global retailer to supply toilet paper, kitchen rolls and facial tissues. The contract is expected to be worth over £10m per annum and further consolidates Accrol's position as a major player within its industry.

Accrol could benefit from a downturn in the UK following the EU referendum. Over 50% of its sales are generated from the discount market segment and if consumers trade down to cheaper toilet paper and kitchen rolls, then its sales could rise. And with Accrol being significantly hedged against currency movements for the current financial year, its medium-term outlook remains bright.

On this topic, Accrol is on track to meet current guidance for the full-year and although it's a small and relatively risky stock to own, it could prove to be a somewhat resilient buy over the medium-to-long term.

Small and relatively risky made me smile, clearly written by a journalist

Contracts in most of the major retailers and discounters

A product group everyone buys

New £10 million contract at factory prices

Strong distributor base selling products on their behalf

Excellent 'Away from Home' business

Positives from the leave vote

I wish all companies were this small and risky, I would buy them all day!

DYOR :-)

With expansion it would be good to see new manufacturing premises added, just so it spreads the risk of all being under one roof.

Good and valid point dreamcatcher, with the caveat that the increase in overheads by doing that such as rates,general infrastructure, insurance, utilities and everything else involved in additional premises, is more than covered by an increase in sales and associated margins.

Just concerned if the factory failed for reasons like a fire etc production would cease.
From an investors view 2/3 production warehouses/ units would lessen worries.


In September 2015, there was a fire within the embossing unit of one of the converting lines. The line was
back up and running within one week with no disruption to customer orders. The costs of repairs was
£158,000.

Accrol currently has four warehouses providing 3,500 tonnes of storage for finished goods, allowing
for at least two weeks supply, a key criteria for certain Multiples.

11 July 2016



Accrol Group Holdings plc (the "Company" or "Accrol")

Deferred Share Buyback



Accrol Group Holdings plc, the AIM listed leading independent tissue converter, today announces completion of the buyback of deferred shares in the Company.

The Company has bought back 27,476,142 deferred shares of £0.001 each (the "Deferred Shares") held by shareholders of the Company on the share register as at 1 June 2016, for total consideration of £1 (the "Share Buyback"), further details of which can be found in the Company's AIM admission document dated 2 June 2016.

Following the Share Buyback there will be no Deferred Shares in issue and the issued share capital of the Company will consist of 93,012,002 ordinary shares of £0.001 each.

ST in this weeks IC - Analysts predictions that revenues will grow by 15% to £138m in the financial year to end April 2017 to produce a near 10% hike in cash profit to £16.4m and deliver pre-tax profit of £13.4m. On that basis ,expect EPS of 10.7p and a dividend per share of 6p.I fully expect the board to reiterate current year guidance, especially as likely weaker UK economic conditions after the EU referendum is great news for the company.

On Monday, Accrol Group Holdings PLC (ACRL:LSE) closed at 117.00, 0.01% below its 52-week high of 116.99, set on Jun 10, 2016.


Just need the whole country to go down with the sh-ts. :-))

Full year results for the year ended 30 April 2016

RNS


RNS Number : 9182E

Accrol Group Holdings PLC

22 July 2016




22 July 2016



Accrol Group Holdings plc (the "Company" or "Accrol")

Audited full year results for the year ended 30 April 2016

Accrol Group Holdings plc, the AIM listed leading independent tissue converter, today announces its audited results for the financial year ended 30 April 2016.

Financial Highlights1

· Revenue increased 17% to £118m (2015: £101m)

· Adjusted Gross Margin increased 2.1% to 28.1% (2015: 26.0%)

· Adjusted EBITDA of £15.0m, up 22% (2015: £12.3m)

· Continued strong cash generation year-on-year

· Net debt reduced by £1.1m

· Successful IPO on London Stock Exchange's AIM market on 10 June 2016

Operational Highlights1

· 35% market share of the Discount sector (Discounters accounting for 69% of revenues, up 6% on 2015) after contract wins during the year

· 15% increase in sales to Multiples

· Focus on Private Label products which are taking market share from Brands

· Continued investment in machinery with £3.2m invested in two high-speed converting lines

· Capacity increased to 118,000 tonnes with a further 25,000 tonnes to be added

· UK exclusivity secured for a new luxury tissue, NTT (New Textured Tissue)

Commenting on the results, Steve Crossley, Accrol's newly appointed CEO said:



"I am delighted to report a strong first set of results following our listing on AIM in June. FY16 has been a very successful year for Accrol and our focus on supplying Private Label products to both Discounters and Multiples has generated 17% revenue growth. We have continued to invest in new capacity as we ready the business for the next stage of our strategic plan. The current year has started encouragingly and we remain confident in the outlook for FY17."



The Company's annual report for the year ended 30 April 2016 (including notice of the annual general meeting to be held at Stanley House Hotel, Mellor, Lancashire, BB2 7NP on 30 September 2016 at 11am) (the "annual report") will shortly be available for downloading from the Company's web site at http://www.accrol.co.uk/investor-relations/.



Notes: (1) 2015 numbers based on unaudited proforma for 12 months ended 30 April 2015.

-------------------------------------------------------------------------------------------



Friday 22 July 2016 1:26pm




Woof: Discount loo roll company targets top dog Andrex after Brexit boost





William Turvill

I write about mergers and acquisitions (M&A), deals and investment for City A.M. [..] Show more


A discount loo roll company which took a punt on floating shortly before the EU referendum believes Brexit provides an opportunity to target the big dogs of the industry. Namely, Andrex.

The Northern company today reported its first results since its initial public offering (IPO) on the alternative investment market (Aim).



Revenue increased by 17 per cent to £118m in the year to 30 April, with adjusted earnings before interest, taxation, depreciation and amortisation (Ebitda) of £15m – up 22 per cent.


Accrol’s decision to float in June stood out at a time when many other firms were understood to be holding back from making IPO decisions amid referendum uncertainty. After the Brexit vote, a number of IPOs have been cancelled or postponed.

But Accrol has no regrets.

Chief executive Steve Crossley told City A.M.: “I think in hindsight it’s been very good timing for us. There were a lot of comments in the marketplace at the time, around ‘are you you sure you should not be waiting?’” But he added that the “the timing has proved to be nothing but very good”.

The company also believes the Brexit vote, and the chances of a recession, presents it with an opportunity.

“As I cast my mind back to 2008, the real winners… were the discounters,” said Accrol’s chief financial officer James Flude.

“We are the leading player in that [discount] sector, it is a sector that it growing at 10 per cent per annum. We’re primarily supplying private labels… which is taking share from brands. We’re well positioned to take advantage of some of those changes.”


Asked what brands Accrol can challenge, Flude said: “As we understand it, and from reading the trade press, Andrex is the market leader – which is about… a quarter of the market – is declining at something like eight per cent per annum.

“And there was an article in Tissue World a couple of issues ago where the UK marketing manager talked about Andrex and its decline. And if you read between the lines, they were basically saying that it’s difficult to sell products when they’re not on promotion.”

He believes Accrol’s tissue products offer better value for money than pricier rivals, adding: “You touch and you feel it, there’s not a lot of difference in the product, but there’s a 30-35 per cent difference in the price.”

ST in IC today - on a forward PE ratio of 10, and offering a prospective dividend yield of 5%, buy.

it doesn't move a lot and nor is there any volume

patience. :-))

Seems a large spread price today? When a stock has a low trading volume, it is considered illiquid because it is not easily converted to cash. As a result, a broker will require more compensation for handling the transaction, accounting for the larger spread

IC - As IC's Simon Thompson flagged in June, it's always worth asking why family owners of a profitable company decide to sell part of their holdings, but the listing allowed the Hussains and their private equity fund backer Northedge , to pay down debts after a period of expansion.
Despite the strengthened balance sheet, the company remains lowly valued on 11 times earnings for the year to April 2017, has a punchy dividend yield and is well established in a largely unchanging sector. Little wonder that the Hussain family has kept some skin in the game.

Seems to be a seller in 25,000 lots. Good rise today.

2nd September 2016



Accrol Group Holdings plc (the "Company" or "Accrol")

New manufacturing facility in Leyland, Lancashire to support the Company's growth plans



Accrol Group Holdings plc, the AIM listed leading independent tissue converter, is pleased to announce that it has reached an agreement with Lancashire County Developments (Property) Ltd (the economic development arm of Lancashire County Council) to lease a new 168,000 sq. ft. facility in Leyland, Lancashire. The new facility will support the Company's continued growth with both the Discounters and the Major Multiples in the UK.

The new property will initially house two high speed tissue converting lines purchased by Accrol in April 2016 and also provide finished goods warehousing space, with potential to add two further converting lines if required.

Installation and commissioning of the first two lines will take place during late 2016, with manufacturing planned to start in January 2017. The project is expected to create around 80 new jobs.

Commenting on the new facilities, Steve Crossley, Accrol's CEO said:



"This additional capacity underlines our strategy of investment ahead of growth in state-of-the-art machinery and facilities. It will position Accrol to benefit from underlying organic growth in the Discount sector and enable further growth with the Major Multiples. At the same time, we will focus on improving efficiency at the existing Blackburn sites to further increase our total capacity

Large buys today.

Large buys today.

Forecast Key Dates

Next AGM Confirmed 30/09/2016
Next year end (to be reported) 30/04/2017
Next prelim announcement Approximate 24/07/2017
Next annual report due Approximate 04/09/2017
Next interim announcement Approximate 25/12/2017

New high.:-))

And in my opinion with plenty more to go, can't call it but even at this level will be a multi-bagger.

Was hoping it would fall to stock up on more and if it does I most certainly will

All good for me glad I got in at the IPO should have got more then, but then isn't that always the way when you have a good one

Good to hear from you Stevesham. I'm up 16% now. :-)) This will move with the installation of the new machine/ machines and any announcements at the agm.

Hi Dreamcatcher love your posts, and yes this is a good solid one for pure growth I so need to buy more when prudent to do so

16% for me too, which if I am right is only the tip of the iceberg

I think if it drops below £1.20 I could be quite easily tempted to get more, however I really can only see this going one way and that is up!

Bought more today Stevesham, sitting on a good holding now.

Nice 300,000 @ 130p


http://www.moneyam.com/trades/ACRL

Excellent, and congratulations on your new purchase! I am so tempted for more.....

They will head towards 200p perhaps by the new year or early part of.

RNS Number : 2527L
Accrol Group Holdings PLC
29 September 2016
 
This announcement contains inside information
 
Accrol Group Holdings plc (the "Company" or "Accrol")
 
Director's Dealing
 
Accrol Group Holdings plc, the AIM listed leading independent tissue converter, is pleased to announce that is has been notified that Stephen Crossley, CEO of Accrol, has purchased 100,000 ordinary shares of £0.001 each ("Ordinary Shares") via his SIPP on 29th September 2016 at a price of 132p per Ordinary Share.

Following this transaction, Stephen has an interest in 100,000 Ordinary Shares, representing approximately 0.1 per cent. of the Company's issued Ordinary Share capital.
 
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

A £132 grand spend by the CEO shows confidence. Lets hope for a good future.

AGM -NOTICE IS GIVEN that the Annual General Meeting of Accrol Group Holdings plc will be held at Stanley House Hotel, Mellor, Lancashire BB2 7NP on 30 September 2016 at 11am for the following purposes:

AGM notes

New high. :-))

Accrol general meeting. some good warehouse pictures


Next Event
30/04/2017
Next year end (to be reported)

Good large 25,000 and 100,000 buys. On the way now.


http://www.moneyam.com/trades/ACRL

Indeed well on the way and it's not going to drop to my target to buy more at £1.20, this I think will easily double.

Going to look at any dips (I doubt there will be any) and top up, better to average up than average down!

DYOR GLA :-)

ST of IC today - When a director splashes out over £100,000 buying shares in his company it’s always worth further investigation. I didn’t have to do much research in the case of Accrol (ARCL:140p), the Aim-traded Blackburn-based maker of toilet rolls, kitchen rolls and facial tissues, as this is a business I know well, having recommended buying the shares when they floated at 100p in the summer ('Clean up with Accrol', 6 Jun 2016), and subsequently reiterated that advice at 118p (‘Brexit winners’, 1 Aug 2016).
The fact that chief executive Stephen Crossley has just invested £132,000 of his own money buying 100,000 shares at a 32 per cent premium to the float price tells a story about Accrol’s trading prospects. Higher consumer demand for private-label products is helping drive ongoing strong sales growth from discount retailers, a segment where the company has a 35 per cent market share, as is management’s ability to cross sell multiple products to new clients. Maiden results have done nothing to alter my earlier positive stance: like-for-like sales rose by 17 per cent to £118m in the year to end April 2016, and analyst Mike Allen at house broker Zeus Capital expects Accrol to maintain this heady growth rate in the current financial year, pencilling in revenue of £138m.
On this basis, expect cash profits to rise by around 10 per cent to £16.4m to produce pre-tax profits of £13.4m and EPS of 11.5p in the 12 months to end April 2017. This means Accrol’s shares are being valued on a forward PE ratio of 12, a rating that fails to acknowledge its potential to continue to grow earnings at a double digit rate for years to come. Indeed, for the following year to end April 2018, Mr Allen believes that Accrol can lift revenues to £156m, increase both cash profits and pre-tax profits by £2.2m, and deliver EPS of 13.4p to reduce the forward PE ratio to 10.5. I am comfortable with those estimates.
The current rating also fails to fully reflect the company’s cash generation. Indeed, net debt is expected to fall to £16m by end April 2017, a sum equivalent to one times cash profits and less than 30 per cent of shareholders funds. So, with profits growing strongly, and the balance sheet modestly geared, the board can recycle cashflow into a progressive dividend. Guidance is for a 6p a share payout in the current year, implying the shares offer a 4.4 per cent prospective dividend yield, rising to around 6.25p a share the year after.
In the circumstances, it’s hardly surprising my 130p target price has proved too conservative and I now feel that a rating of 12 times EPS estimates of 13.4p for the 12 months to end April 2018 is a more realistic valuation. This implies a new target price of 160p, and one that more accurately takes into account Accrol’s low balance sheet gearing, and prospects of delivering double digit earnings growth. Buy.

Details of dividend below -



EVENT
TIMING
RECENT/UPCOMING DATES
Financial year
Year end 30 April
Half year end 31 October

Results published
Full year preliminary results
Our preliminary results for the year ending 30 April 2016 were released on 22 July 2016. These are available on the ‘Company Reports and Presentations’ page and in the ‘Regulatory News’ section of our website.

Interim results
Our interim results for the half year ending 31 October 2016 will be released mid-January 2017.
AGM
Late September
Our 2016 AGM was held on 30 September 2016 at 11am at Stanley House Hotel, Mellor. The AGM Result can be found on the ‘Regulatory News’ section of our website.
Dividends
Interim dividend record date November, paid January
An interim dividend of 1/3 is expected to be paid in January 2017.

Final dividend record date May, paid September (subject to shareholder approval).
A final dividend of 2/3 per share for the year ending 30 April 2017 is expected to be paid September 2017.

Shorting activity = very low


On Thursday, Accrol Group Holdings PLC (ACRL:LSE) closed at 121.50, -13.83% below its 52-week high of 141.00, set on Oct 11, 2016.

Pre-close trading statement
RNS
RNS Number : 4344O
Accrol Group Holdings PLC
07 November 2016
 
This announcement contains inside information
7 November 2016
 
Accrol Group Holdings plc ("Accrol" or "the Company")
Pre-close trading statement
 
Accrol Group Holdings plc, the AIM listed leading independent tissue converter, is pleased to provide the following update on trading.   
The business has made good progress since the start of this financial year and trading has been in line with our expectations. During the six months ended 31 October 2016, the Company has continued to win new business with existing customers in addition to the previously announced new £10m contract gain, which we can now confirm is Lidl.
Installation of two high-speed converting lines in our new 168,000 sq. ft. manufacturing facility in Leyland is well underway and will increase our total capacity to 143,000 tonnes per annum. The premises will initially house the two high speed tissue converting lines we purchased in April 2016 and the increased capacity will support our continued growth with both Discounters and Major Multiples in the UK.
We continue to follow our hedging policy to mitigate adverse movements in Sterling against the US$ and Euro. Following our significant purchase of dollars pre-Brexit, we have increased our facilities and we continue to closely monitor the Company's forward currency positions.
We remain confident in the outlook for the full year and that the strong cash flows generated by the business will support our progressive dividend policy and underpin our continued growth.
The Company's interim results will be announced on Thursday 5th January, 2017.
Steve Crossley, Accrol's CEO, commented:
 
"Since the start of this financial year we have made good progress on our strategic aims and we are increasing our production capacity to enable us to take advantage of new opportunities as they arise.
 
"We are pleased with the new business that we have won since the start of the financial year and with progress on the manufacturing facility in Leyland, Lancashire and look forward to the future with confidence."
 
Ends

ST of IC - And as I pointed out when I first recommended buying the shares when they floated at 100p in the summer ('Clean up with Accrol', 6 Jun 2016), the company has reported compound annual sales growth of 16 per cent over the past four years, and profitably, too. Cash profit increased by 14 per cent in the period to £15m in the 12 months to the end of April 2016, and analysts expect a rise to £16.4m in the current financial year to produce pre-tax profit of £13.4m, EPS of 11.5p and support a dividend of 6p a share. On that basis, the shares are rated on 11 times earnings estimates, and offer a prospective dividend yield of 4.7 per cent, hardly an exacting rating for a company that has a track record of delivering double-digit profit growth and one targeted at the high growth discount sector. Indeed, Aldi and Lidl now have over 10 per cent of the UK retail market and are opening five times as many new stores as all their 'Big Four' rivals combined, so expect them to make further market share gains in the coming years.
So, having raised my target price to 160p when I last rated the shares a buy at 140p ('High fives', 4 Oct 2016), I have no hesitation reiterating that advice. Buy.

ST of IC - And as I pointed out when I first recommended buying the shares when they floated at 100p in the summer ('Clean up with Accrol', 6 Jun 2016), the company has reported compound annual sales growth of 16 per cent over the past four years, and profitably, too. Cash profit increased by 14 per cent in the period to £15m in the 12 months to the end of April 2016, and analysts expect a rise to £16.4m in the current financial year to produce pre-tax profit of £13.4m, EPS of 11.5p and support a dividend of 6p a share. On that basis, the shares are rated on 11 times earnings estimates, and offer a prospective dividend yield of 4.7 per cent, hardly an exacting rating for a company that has a track record of delivering double-digit profit growth and one targeted at the high growth discount sector. Indeed, Aldi and Lidl now have over 10 per cent of the UK retail market and are opening five times as many new stores as all their 'Big Four' rivals combined, so expect them to make further market share gains in the coming years.
So, having raised my target price to 160p when I last rated the shares a buy at 140p ('High fives', 4 Oct 2016), I have no hesitation reiterating that advice. Buy.

Should you ditch Unilever in favour of fast-growing small-cap Accrol?
By Peter Stephens | Fool.co.uk – Mon, Nov 7, 2016 11:23 GMT
Share



Print
Companies:
Accrol Group Holdings Plc
Unilever PLC
RELATED QUOTES
Symbol
Price
Change
ACRL.L
126.00
0.00

ULVR.L
3,382.00
+21.50


Today's update from Accrol (LSE: ACRL) shows that the company is doing all the right things. The tissue specialist (that's kitchen towel, facial tissues and loo roll to you and I) is certainly performing in line with expectations and has excellent growth prospects. But does this mean that it's a better buy than consumer goods peer Unilever (LSE: ULVR)? It's a tough contest against the consumer goods giant. Let's take a look...
New business wins
Accrol's performance in the first six months of the current financial year shows that its strategy is performing well. It has been able to win new business with existing customers while also gaining new contracts such as the £10m deal with Lidl. Accrol is in the process of installing two high-speed converting lines in its new manufacturing facility. This will significantly increase its capacity and support long-term growth, especially with both discounters and major multiples in the UK.
In fact, Accrol could be a major beneficiary of Brexit. The UK economy could endure a challenging period that may end in inflation being higher than wage growth. This could lead to increased pressure on disposable incomes, which may cause shoppers to trade down to cheaper supermarkets and cheaper brands. This could increase demand for Accrol's products and act as a positive catalyst on its future growth.
Accrol is expected to increase its bottom line by 53% in the current year and by a further 22% next year. This is an excellent rate of growth and yet the market doesn't yet seem to have fully priced it in. For example, Accrol trades on a price-to-earnings growth (PEG) ratio of 0.4, which indicates that capital gain prospects are high.
The outlook for Accrol is brighter than for consumer goods peer Unilever. It's forecast to grow its bottom line by 5% in the current year and by a further 10% next year. This puts Unilever on a PEG ratio of 1.9. While this is attractive on an absolute basis, relative to Accrol, Unilever seems to be significantly overvalued at first glance.
However, Unilever offers a much lower risk profile than Accrol. For starters, it's a much more diversified business, with Unilever selling a wide range of goods that enjoy a high degree of customer loyalty. Unilever also has greater geographical diversity than Accrol, which means that its performance should prove to be more stable over the long run.
Unilever's financial firepower is also more impressive than that of Accrol. This means that Unilever is better positioned to invest for future growth, for example in the M&A arena. And with Unilever having a dividend yield of 3.2% which is covered 1.5 times by profit, it has far superior income potential to Accrol, the latter of which currently pays no dividend.
While Accrol is a worthy investment, Unilever's risk/reward profile is superior. Therefore, selling Unilever to buy Accrol doesn't seem to be a wise move at the present time.
But should you sell Unilever for this top growth stock?

Someone clearly buying in, in 18k, 25k and 50k lots. :-))

Someone clearly buying 18k, 25k and 50k lots. :-))

e-mail to me from the company today regarding the dividend -

So sorry to have taken such long time to respond but we were still sorting out the dates of payment etc.

I now have it confirmed that the shares will become ex dividend on 12 January 2017. The interim dividend will be paid to Members of the Registry at close of business on 13 January 2017.

One again, apologies for the delay.

Thanks
Kathleen

Thank you dreamcatcher it's in the diary, appreciate all your posts very helpful....

I have waited a couple of weeks for the info. Mind you the company always answer. Cheers stevesham.

Notice of interim results date change
RNS
RNS Number : 7679R
Accrol Group Holdings PLC
14 December 2016
 
14 December 2016
 
Accrol Group Holdings plc (the "Company" or "Accrol")
Notice of interim results date change
 
Accrol Group Holdings plc, the AIM listed leading independent tissue converter, is pleased to announce that its interim results will be announced earlier than previously reported, now on Wednesday 4 January 2017.
A presentation to analysts will take place at 9.30am on the 4th January at Camarco's offices at 107 Cheapside, London, EC2V 6DN. Please contact Camarco on the details below for further information

Now there is interesting I wonder why?

Do we think they have some great results they need to get into the market to speed up progress? maybe a move from AIM? maybe record results and can't wait to announce an amazing dividend, whatever it is, my belief is it will be amazing

I hope so. The Interim results are going to be announced on the 4th instead of the 5th, only a day in it, :-))

Reading ST of IC today ,perhaps a bid for Accrol may come one day.


The fact that so many small-cap companies are being taken over is noteworthy, a reflection of the fact that cash-generative and modestly geared businesses with solid balance sheets remain attractive to larger rivals and private equity firms, which are able to readily access cheap credit and gear up the target's balance sheet. I don't expect this activity to end any time soon, a good enough reason to continue to search for companies exhibiting solid finances, and where the differential between earnings yields - the reciprocal of the PE ratio - and the cost of corporate debt is such that there is an incentive for an acquirer to offer a bid premium.
A consequence of the ongoing bid activity in my small-cap space, and the fact that I now have run profit recommendations on literally dozens of my share recommendations, is that I am always on the search for new companies to consider commencing coverage on. Aim listings have proved a fertile hunting ground - tissue maker Accrol (ACRL:128p) and student accommodation construction company Watkin Jones (WJG:118p) are two of the small-cap winners in the new issues market I have managed to screen out from this year's offering. Expect more of the same in the coming year, and one in which I believe the ability of stockpickers to generate above-average returns is likely to come into the fore, a challenge I am relishing already.

Seems to have been a steady sell off over the last couple of months.

On Wednesday, Accrol Group Holdings PLC (ACRL:LSE) closed at 120.00, -14.89% below its 52-week high of 141.00, set on Oct 11, 2016.

Hope for a positive set of results in the morning, due to them being pulled forwards.

Good luck DC £££££'s are coming!

This is what I have been waiting for, hope I am not disappointed as I can only see good news being announced and hopefully get some more good news M&A possibly?

Looking for a nice uplift again tomorrow

Hi stevesham, don't mind the M&A's. I hope we do not get news that someone like Andrex has taken them out. Kimberley-Clarke as you know are an American firm that are huge and they purchased Scott Paper along with the brand Andrex.(A British brand)
A takeover a lot further down the road will be welcomed. This company is an ideal
young company and going to be far cheaper to takeover now then in a few years time.

Interim results

Financial Highlights
·     Revenue increased 8.8% to £63.9m (H1 FY16: £58.7m)
·     Gross Profit increased 5.6% to £18.2m (H1 FY16: £17.2m)
·     Adjusted gross margin improved by 1.1% to 28.4% (H1 FY16: 27.3%) through significant currency hedging pre and post EU referendum and negotiated parent reel pricing
·     Adjusted EBITDA increased 1.5% to £7.1m (H1 FY16: £7.0m)
·     Net debt reduced by £3.2m from £23.1m at flotation to £19.9m at 31 October 2016
·     We have significantly increased our foreign currency facilities and have continued with our existing hedging strategy
·     Maiden interim dividend announced of 2p per ordinary share
Operational Highlights
·     Successful IPO in June 2016 raising £63.5m
·     Our market share of discount sector has increased to circa 50%
·     Significant contract wins previously announced with Booker, Poundstretcher and Lidl
·     Early indications that Lidl contract likely to deliver more than £10m in annual revenue
·     New 168,000 sq. ft. manufacturing facility at Leyland, Lancashire progressing on target with production starting end of January 2017
·     Senior team strengthened in Manufacturing, Supply Chain, HR, Procurement and Engineering. Successful and complete transition of key operations from the Hussain Family to the new Operational Board
·     Operational initiatives underway including; price inflation recovery, manufacturing optimisation and supply chain optimisation

This company will soon be noticed . :-))

Someone looks to have sold 775,415 a director maybe at 15.20 pm.

I saw that. Good write up from Shares today, Might need extra machines in the near future.

The 745,000 sale - no current director holds the level. As the company sounds like it has taken over running the business from the Hussain Family, it may be a member selling up.

Another big 1,275.000 supposed sell gone through , yet it's up . Do i buy .

My main concern is that I hope the Hussain family are blocked legally in writing from setting up 5 miles down the road.

Shareholder Information

Shares In Issue

As at 10th June 2016 the number of shares in issue was 93,012,002
Major Shareholders
As at 10th June 2016, significant shareholdings in the share capital of Accrol Group Holdings plc were:

Majid Hussain*
4,652,590
5.00%

Wajid Hussain*
4,652,590
5.00%
Mozam Hussain*
4,646,621
5.00%

NorthEdge Capital LLP**
13,987,377
15.04%

Miton Asset Management Limited
7,700,000
8.28%

Axa Investment Managers UK
8,400,000
9.03%

Schroder Investment Mgt
7,850,098
8.44%

Majedie Asset Management
5,876,414
6.32%

Ruffer LLP
4,504,200
4.84%

Premier Asset Managers
3,600,000
3.87%

BlackRock Investment Mgt (UK)
2,887,410
3.10%

2X 250,000 BUYS

Interim results to 31 oct 2016. Jan 2017


A good read for anyone interested .

I wonder if there is another big sell tomorrow it would be these Hussain family . I thought that the results were good why sell now , maybe of course they were buys .

A huge 750,000 buy as well. Someone selling with a keen buyer .

Interesting from the admission document - Each of the Directors, the Proposed Directors and the Selling Shareholders who will hold Ordinary Shares following Admission have undertaken, pursuant to the Placing Agreement: ● for a period of 12 months from Admission, not to dispose of any of the Ordinary Shares in which they are interested at Admission, except with the permission of Zeus Capital and in certain customary circumstances; and ● for a further period of 6 months, to comply with certain requirements designed to maintain an orderly market in the Ordinary Shares.

A couple of investors on other sites who took part in the webinar with the company, sound impressed with the company and management.

Only just had money from Creston takeout so lost chance at 125 ish , might wait for pullback .

pullback ? lol .There might well be after the dividend qualifying date. Does tend to fall away without news.

Two small capswith 25% upside after the results

ST of IC today - My original 130p target price has now been taken out and my new target price range of 155p to 160p equates to a reasonable 10 times earnings estimates, and is supported by a near 4 per cent prospective dividend yield. Buy.

Seems AXA was selling last week , gone below 5% , still keep an eye here .

I see that, I have just reduced my holding as well. Will purchase back on any weakness.

Cheers VICTIM

Holding (s) company Axa reduces

Ex divi tomorrow. Would not think too many bought in for a 2p dividend, so hope there is not a big sell off.

Accrol papers webinar

http://bit.ly/2i8Tkg1

On the radar of investors now.

Still looks like a seller, but otherwise a good day.

I thought this would tiptoe down , then i'd buy , bugger .

Looks like from the video I posted there is a fair bit of news due ie warehousing, director buys, when permitted.

If food inflation creeps in supermarkets, shoppers may just have to trade down in their shopping. Also if they swap to the german discounters, this company is win,win.

Now don't tell everyone .

I don't like the word discounters, Aldi food/drink is very good.

I do small purchases there , but we have two stores here and they are applying for another to be built .

Accrol Group Holdings is in the household goods & home construction sector and is currently trading at 147.00p per share. In the last year Accrol Group Holdings's share price has ranged from 100.50p to 148.79p.

Accrol Group Holdings PLC (ACRL:LSE) set a new 52-week high during today's trading session when it reached 151.44. Over this period, the share price is up 37.67%.

Hit £1.55 today. 5x10,000 late buys.

Top sliced today and topped up (FREE)


Accrol Group Holdings PLC (ACRL:LSE) set a new 52-week high during today's trading session when it reached 156.50. Over this period, the share price is up 42.27%.

A couple of big holding sells today.

Large seller, a large buyer as well. :-))

Dividend Friday.

In need of news.

Sold my last holding, falling daily.

Probably tick up again in the future .

Put the funds in sron and sold and re-bought. :-)) profit just dwindling for me here.

I wonder if he gets loo rolls free for life. lol


Official opening of new manufacturing facility
RNS
RNS Number : 7352B
Accrol Group Holdings PLC
06 April 2017
 
6 April 2017
 
Accrol Group Holdings plc (the "Company" or "Accrol")
Official opening of new manufacturing facility in Leyland, Lancashire
 
Accrol Group Holdings plc, the AIM listed leading independent tissue converter, today announces the official opening of its new 168,000 sq. ft. manufacturing facility in Leyland, Lancashire with the unveiling of a ceremonial plaque by Lord Shuttleworth, Lord-Lieutenant of Lancashire.
This facility has had two tissue converting lines installed, which will increase Accrol's total converting capacity to 143,000 tonnes per annum.  Manufacturing began at the end of January 2017 and output will steadily increase as new shift patterns are added over the coming weeks. When both lines are fully manned they will create over 80 new jobs, taking Accrol's total number of employees to almost 600, all of whom are based in Lancashire.  The new facility has space for a further four converting lines.
Steve Crossley, Accrol's CEO, commented, "This new facility marks another milestone in Accrol's development, increasing our total production capacity by 25,000 tonnes to 143,000 tonnes per annum."

ST of IC upgraded his target price today 180p

Trading Update, New Facilities & Notice of Results
RNS
RNS Number : 1805F
Accrol Group Holdings PLC
16 May 2017
 
16 May, 2017
 
This announcement contains inside information
Accrol Group Holdings plc (the "Company" or "Accrol")
Trading Update, New Warehousing and Distribution Facilities and Notice of Results
 
Accrol Group Holdings plc, the AIM-listed leading independent tissue converter, provides the following trading update for the twelve-month period ended 30 April 2017.
The Company has had a strong year of growth in its first year as a publicly listed business following its successful IPO on AIM in June 2016, and is pleased to announce that it has performed in line with market expectations despite some challenging macro-economic factors.
Over the last twelve months, Accrol has consolidated its position as the leading supplier of tissue products to the Discount sector and has continued to invest in its growth plans with the opening of a new 168,000 sq. ft. manufacturing facility in Leyland, Lancashire in January 2017, increasing production capacity to 143,000 tonnes per annum.
The Company is also pleased to announce today that it has agreed a 10-year lease with Orbit Developments on a 368,000 sq. ft. warehouse in West Lancashire.  The warehouse will store finished goods and provide central distribution facilities to all UK customers, enabling Accrol to simplify and consolidate its existing warehouse facilities. Warehouse management and national logistics will be contracted out to NFT.
 
Steve Crossley, Accrol's CEO, commented:
 
"We are pleased to announce that, despite a less favourable macro-economic environment, we have performed in line with expectations in our maiden year as a publicly-listed business. We have continued to make progress with our growth plans, extending our relationships with both new and existing customers and investing in our infrastructure for the future.
 
 
Final results for the year ended 30 April 2017 will be announced on 10 July 2017.
 
Today, the Company will be holding an Investor Day at its Head Office in Blackburn, Lancashire. There will be no material information disclosed that is not already in the public domain.

Large buys going through.

Andrex reduces size of toilet rolls

Yeah it's a bit like all those chocolate bars dream , the ones that's half the size they were .

Good chance for this company. :-))

Finals Monday 10 July

Preliminary results for year ended 30 April 2017
RNS
RNS Number : 5118K
Accrol Group Holdings PLC
10 July 2017
 
This announcement contains inside information
10 July 2017
Accrol Group Holdings plc
Preliminary results for the twelve months ended 30 April 2017
 
Accrol Group Holdings plc, the AIM listed leading independent tissue converter, is pleased to announce its preliminary results for the twelve months to 30 April 2017.
 
Financial Highlights
 
·      Revenue increased 14.2% to £135.1m (FY16: £118.2m)
·      Gross Profit increased 9.3% to £37.7m (FY16: £34.5m)
·      Adjusted gross margin(1) was  27.9% (FY16: 28.1%) supported by favourable parent reel pricing and significant currency hedging
·      Adjusted EBITDA(1) increased 6.8% to £16.1m (FY16: £15.0m)
·      Adjusted profit after tax(1) increased 57.3% to £11.0m (FY16: £7.0m)
·      Profit after tax increased 29.3% to £7.4m (FY16: £5.7m)
·      Continued strong cash generation in a period which included a £3.6m repayment of loan note interest
·      Net debt reduced by £41.7m to £19.0m (Net debt / Adjusted EBITDA reduced from 4.0x to 1.2x)
·      Basic EPS of 9p and adjusted EPS of 12p
·      Final dividend proposed of 4p per ordinary share giving a total of 6p per ordinary share for the full year
 
Operational Highlights
 
·      Successful maiden full year as a publicly listed company, with a solid trading performance
·      New contract wins have seen market share grow to over 50% of the Discount Sector
·      Good progress made in building a platform for future growth
·      Key new hires to operations and management functions
·      Opened new 168,000 sq. ft. manufacturing facility at Leyland, Lancashire, with two tissue converting lines commissioned and a third line expected in FY18
·      Supply Chain Optimisation plan implemented to improve and simplify warehousing and logistics through a 368,000 sq ft. central warehouse at Skelmersdale and managed by NFT Distribution
 
Steve Crossley, Chief Executive Officer of Accrol, commented:
"This has been a year of positive change for Accrol as we have transitioned to life as an AIM listed company. We have won new contracts and increased our share of the Discount Sector to over 50%."
 
"We continue to build a platform for future growth, having made a significant investment in our new manufacturing facility at Leyland to create extra capacity. A new finished goods warehouse in Skelmersdale, announced in May 2017, will provide central storage and distribution facilities for our customers, improving our supply chain efficiency and enabling us to build on our market position."
 
"Increasing input costs, driven by exchange rates, are impacting most product categories in UK retail and like all UK manufacturers, we continue to seek inflation recovery. There are positive signs, with some retailers increasing consumer price points, although it is slower than we expected. We believe that as price increases come through fully in the market, this will continue to drive shoppers to seek good value in the Discount and Multiple own-label sectors.''
Note 1: Non-GAAP measures are reconciled in note 25
 
There will be an analyst presentation to discuss the results at 9am on 10th July 2017 at the offices of Camarco. Analysts interested in attending should contact Kimberley Taylor on +44 203 757 4999.
 
The Company's annual report for the year ended 30 April 2017 (including notice of the annual general meeting to be held at Accrol's Head Office in Blackburn on 6th October 2017 at 2pm) (the "Annual Report") will shortly be available for downloading from the Company's web site at http://www.accrol.co.uk/investor-relations/.

08:40 10/07/2017
Broker Forecast - Liberum Capital issues a broker note on Accrol Group Hldgs Plc
Liberum Capital today initiates coverage of Accrol Group Hldgs Plc (LON:ACRL) with a buy investment rating and price target of 200p. Story provided by StockMarketWire.com

Someone elsewhere mentioned that this stock is tipped in Shares magazine this week. Not seen it myself.

Full page (page12 ) juzzle

Simon Thompson on investor's chronicle wrote, in answer to a reader comment the other day, that "I am publishing an update on Accrol on Monday 24 July."

(posted by glawsiain elsewhere)

Thanks, will e interesting to read. Shares seems to think there will be plenty of upside.

Haven't seen that Simon Thompson update yet. Not among this latest search on Google News: Accrol news

EDIT: I found this analysis of Accrol's Return On Equity interesting: R-o-E, Accrol

cheers juzzle

ST of IC run profits. Was going to buy back in, on hold for now.

Posting of Accounts & Notice of AGM - Date change
RNS
RNS Number : 4577N
Accrol Group Holdings PLC
09 August 2017
 
9 August 2017
 
Accrol Group Holdings plc (the "Company" or "Accrol")
Posting of Accounts and Notice of AGM - change of dates
 
Further to the announcement of the Preliminary Results on 10 July 2017, the Company announces that it has today posted its Annual Accounts for the year ended 30 April 2017 together with a Notice of Annual General Meeting ("AGM") to its shareholders and that copies are available on the Company's website, www. Accrol.co.uk. The AGM of the Company will be held sooner than previously notified and will now be on 22 September at 10.00am. The venue remains as Accrol's Head office in Blackburn.
 
At the AGM the final dividend of 4 pence per ordinary share will be proposed. Subject to shareholders' approval, this dividend will be paid on 26 September 2017 to shareholders on the register on 1 September 2017. The Company's ordinary shares will become ex-dividend on 31 August 2017 (all such dates being earlier than previously notified).

Questor today -

Questor: boring shares are the best – so buy this kitchen-roll maker for its 5.8pc yield

Anyone subscribing to the MoneyAM Level 2 platform please take note that most days it is not reporting the correct Trade High nor Trade Low information and "some days" not reporting the correct Opening Price or Closing Price.

The reason is because MoneyAM's Level 2 system is not correctly sensing the Auto Trades or Ordinary Trades correctly so is wrongly reporting them

There's a shock then even suspension of trading , never expected anything like that , never bought these thankfully .

I did !

Wonder how big the fine will be given they fear its' materiality - and alongside that - how poor must management have been to allow this to happen?

I did too and made money and took dividends

I sold in two halves so no damage from this, but feel for other shareholders, seemed like a great company, and was even considering buying back in, but really don't care what the price will be when it (or if) it starts trading again, as they say, I'm out (and for good)

Hope it does all work out for them, and the staff and other shareholders.

Same here Steve. They seem to have reversed the results announced on the 10 July (only 3 months since the announcement and and 6 months into a new year)

From Shares -

Accrol’s maiden results for the year to April (10 Jul) revealed a 58% surge in adjusted pre-tax profit to £13m on sales up 14.2% to £135.1m

Dreamcatcher, I have to admit I was both surprised and disappointed, I know the company from a professional point of view (haven't used them though for over 12 months which I suppose should have told me something"!) however never saw this coming, but there you go over and out!

Onto the next which is proving tricky as the ones on my list I either already own, or are looking toppy, love the research, even more now the nights are getting dark earlier

If you come up with any Shares like Fevertree or Wandisco let me know. :-))

Now that would be nice.

My latest three were Taptica, XLM and RPC, but I did get in a couple of weeks ago, and they are doing quite nicely thank you

Also Royal Dutch Shell, that has flown the last few days, its a tough one to either take the profit on this, or just keep long term while the dividend is so good so capital growth and dividend, choices, choices!

Not recommending anything though DYOR as they say.......

Steve - XLM and TAP are among mine too, on my 'Portfolio 69' thread (69) along with IQE, LTG and half a dozen others ;-)

I bought ACRL into that portfolio in July, but luckily ditched it quite quickly having become doubtful in the first two weeks (as posted there, posts 5 and 20, sold Aug 8 for a 9% loss).

Hi Juzzle, have to say ACRL was a real disappointment, I knew the company and never suspected anything like that, at least I made a profit took a dividend and escaped!

Still no dividend from XLM, so sold when price dropped, but after yesterdays RNS back in for the long haul (hopefully)and it's up again so far today.

SCH is looking good to me, not much activity on level 2 that I can see other than MM's so may take some of these to replace PAYS (sold most but still hold a few, just to see what happens!)

IQE is interesting, but was a little put off by trading at over 30 times earnings, but on the watchlist if it gets to £1.18 or less.

IQE has been a cracker for those who have already been holding even if only for the last 6 months
my records show that i bought in feb/march '17 at an average of 51.2p, so though sp has dropped back from about 150, the gain at 139 is hardly to be sneezed at

I couldn't agree more, only wish I would have spotted it earlier and well done to those that already have it, now if only I could buy some at 51.2p............no answer required as I am sure it will be something like no *%$" chance!

Not pushing this on anyone but GAN looking better with internet gaming getting legalised in USA , take a look at latest RNS could be in at the start here .

A piece in the Times today - The company will this week ask for £18m from stock market investors. New shares are likely to be priced at 50p each; Accrol listed on AIM in June last year at 100p

Ouch!!!!!!!!!!!!!!

Interim Results for six months ended 31 Oct 2017
RNS
RNS Number : 4606C
Accrol Group Holdings PLC
22 January 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

22 January 2018

Accrol Group Holdings plc
("Accrol", the "Group" or the "Company")

Unaudited interim results for the six months ended 31 October 2017
and
restructuring update

Accrol Group Holdings plc (AIM: ACRL), an independent tissue converter and supplier to a number of the UKs largest wholesalers and retailers, announces its interim results for the six months ended 31 October 2017. In the six month period, the Group incurred an operating loss of £5.7 million compared to a reported operating profit of £3.9 million in the prior year first half.

Following the appointment of Gareth Jenkins as CEO in September 2017 and the identification of a number of significant issues affecting the Group's performance and financial liquidity, the Company requested a suspension of its shares on 5 October 2017. After engagement with shareholders and development of a series of business recovery action plans, Accrol's shares were relisted on 20 November 2017 in conjunction with a planned share placement of £18 million (gross of expenses) which was approved by shareholders on 8 December 2017. At the same time, the Company renegotiated its banking facilities with revised financial covenants which took account of the projected operating performance of the Group.

As previously announced, this has been a difficult period for the Group and its shareholders and a range of business challenges are now being addressed by a new executive leadership team. These will take some time to resolve but progress is being made.

H1 FY18 financials:

· Revenue increased by 13.1% to £72.3m (H1 FY17: £63.9m)
· Gross profit declined by 34.7% to £11.9m (H1 FY17: £18.2m)
· Adjusted gross margin(1) 10.7% lower at 17.7% (H1 FY17: 28.4%)
· Adjusted EBITDA(2) reduced by £8.7m to a loss of £1.6m (H1 FY17: profit £7.1m)
· Net debt rose by £9.4m to £29.3m (H1 FY17: £19.9m)

December 2017 Placing

Post the half year end, the Company successfully raised £16.8m (net of expenses) by way of a placing.

Statement from Gareth Jenkins, Chief Executive Officer of Accrol
It is with disappointment that, in my first communication to shareholders, I have to address the fact that the performance of and short-term outlook for the Group have been so contrary to prior expectations. I do believe, however, that the capabilities of this business are significant and, if well managed, it can deliver a considerably improved performance in the medium term.

The Group's recent problems have arisen from the combination of adverse factors, including:
· rising input costs - tissue cost growth following upstream pulp cost growth;
· adverse FX - forward hedging of USD for paper purchases protected results immediately after the Brexit inspired Sterling devaluation. Significant ongoing, fixed period USD financial hedges, however, were taken out at rates which have become adverse to current market spot rates. These hedges are negatively impacting the Group's financial performance in the short term; and
· internal cost growth - increases in the fixed cost base as a consequence of the new logistics arrangements at Skelmersdale, the new Leyland plant and changes to shift patterns in mid-2017, at a time when the business was managing an overly complex product portfolio.

As these problems came to light in early in October 2017, action was taken to manage liquidity issues by extending credit from suppliers and reducing inventory levels. Whilst this was necessary under the circumstances, it put additional pressure on supplier relations and on customer service levels.

I am pleased to report that significant progress is being made on tackling these issues:

· the leadership team has been strengthened with Don Coates joining as COO. He has extensive experience in business turn around and operational improvement;
· price increases being negotiated and agreed with customers are starting to impact results positively;
· the product range is being rationalised, the benefits of which should flow through progressively during 2018;
· a number of cost savings initiatives are being pursued, including the previously announced reduction in headcount;
· an increased focus on investing the necessary funds to maintain equipment efficiency; and
· current cash flow projections reflect the improved operating outlook but will also be subject, in the short term, to the adverse FX contracts and the payment for a new operating line, which will be installed at the Leyland plant in the summer of 2018. The combined effect of which is expected to increase net debt modestly until mid 2018 before declining thereafter.

In addition to the foregoing actions, I have met personally the Group's major customers and am encouraged by the positive attitude they have to developing further business opportunities with Accrol, despite the recent service challenges. I have also met the Group's major suppliers. They remain supportive of doing business with Accrol and of working with us on our ongoing product reformulation plans.

Outlook

The Board expects that recent and planned actions will drive Accrol forward. Whilst the Board continues to expect a small loss at the adjusted EBITDA level for the financial year ending 30 April 2018, the Board is comfortable that the Group will continue to operate within its borrowing covenants while work on the turnaround continues and the directors look forward to the longer-term future of Accrol with confidence.

The directors are confident the 12-month restructuring programme being implemented by the Company's new management team, combined with an invigorated focus on the right customers, products, markets and people, will create a much stronger base on which Accrol can rebuild its profitability and, ultimately, shareholder value.

The Board expects the Company to return to profit at adjusted EBITDA level in the year to 30 April 2019. It remains the Board's intention to return to the dividend list at the earliest appropriate opportunity.
Gareth Jenkins, Chief Executive Officer of Accrol, said:

"I believe that actions we are taking and plan to take to effect the turnaround at Accrol will put the business back on track towards its goal of becoming a market leader in the supply of innovative, high quality, tissue based products to the UK's largest retailers and ultimately the consumer. I continue to believe Accrol can achieve this by investing and leading in operational excellence, to ensure that our customers get the best value product with market leading quality and service."

Accrol Group CFO resigns
StockMarketWire.com
Accrol Group Holdings is searching for a new chief financial officer after James Flude resigned from the company to purse other interests.

Martin Leitch would assume the role on interim business while a replacement is found, Accrol said.

At 3:18pm: (LON:ACRL) Accrol Group Hldgs Plc share price was +0.5p at 36.5p


Story provided by StockMarketWire.com

Down the toilet after poor trading update today. Down 63%

I wasn't going to, I really wasn't but just had to buy these today again, looks like it could be a takeover target, got in at 16p

Jeesr Industries are the ones building a stake, will be watching like a hawk though, made money last time and had dividends before it crashed and burnt, but I think it could be a Phoenix, any signs of trouble and I am gone!

Check the RNS as I can't seem to post working links

DYOR

Well done.

Cheers DC, hope I did the right thing, can't see too much downside just 16p per share :-)

The plan is to double my money and go again (subject to any news or movements I don't like)

Very strange, the whole episode. I will be watching with interest.

Some big selling today.

I'm out, nice little profit was worth it, going to watch now see if any holdings are going to be increased and may jump in and out again, not one long term for me though

Well done.

Thanks DC, will look to get in again, depending on what happens, but not a fan of the company, don't have to like them to make money :-)

Possible good increase here.

Just for interest and I have no position here due to recent activity.

I have however have dipped in and out and grabbed some profits, and did well out of the IPO.

I thought the Jeesr increased holding was very good, along with the increase from Schroder, however the other thing that has sparked a renewed interest for is the following link.

https://www.linkedin.com/feed/update/activity:6405395784212242432/

If the link doesn't work, Accrol are looking at a new wrapping machine capable of 200 packs per minute, and a bundler (preparing packs ready for outers) capable of 25 per minute.

Manufacturer here http://tmcspa.com/eng/prodotti/rolls

Just get a feeling they are gearing up production and planning for the future

Moving towards the top of my watchlist, but not ready to reinvest just yet

Just thought this may be helpful.

Steve

Cheers Steve. Sounds like the company has a good rescue plan. If this company produces the Saxon superior rolls for Aldi, they are of a very high quality and very reasonably priced. The whole episode from the sale date has been to say strange.